Valuation: Eli Lilly and Company

Capitalization 736B 636B 597B 541B 999B 63,332B 1,130B 6,979B 2,715B 28,993B 2,761B 2,701B 105,912B P/E ratio 2025 *
38.6x
P/E ratio 2026 * 29.2x
Enterprise value 760B 658B 617B 559B 1,033B 65,466B 1,168B 7,214B 2,807B 29,969B 2,854B 2,792B 109,480B EV / Sales 2025 *
12.8x
EV / Sales 2026 * 10.5x
Free-Float
99.81%
Yield 2025 *
0.73%
Yield 2026 * 0.82%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.90%
1 week+6.43%
Current month+11.07%
1 month+14.51%
3 months+0.72%
6 months+3.83%
Current year+6.13%
More quotes
1 week 767.59
Extreme 767.5929
825
1 month 709
Extreme 709
825
Current year 677.09
Extreme 677.0912
935.62
1 year 677.09
Extreme 677.0912
972.53
3 years 283.11
Extreme 283.11
972.53
5 years 129.21
Extreme 129.21
972.53
10 years 64.18
Extreme 64.18
972.53
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 2016-12-31
President - -
Director of Finance/CFO 48 2024-09-08
Director TitleAgeSince
Director/Board Member 64 2004-12-31
Director/Board Member 69 2009-03-31
Director/Board Member 53 2011-12-11
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.90%+6.43%-6.73%+181.77% 736B
+0.28%+1.34%+7.94%-6.59% 378B
-0.58%+5.27%-47.91%+36.67% 355B
-0.70%+0.66%+13.34%+38.85% 338B
-1.06%+0.56%+8.93%-11.79% 266B
-0.93%+0.08%+2.26%+20.37% 235B
-0.40%+1.89%-12.18%+12.68% 232B
-0.13%+3.47%-36.89%-3.30% 205B
-0.70%+1.68%-1.14%+25.25% 159B
-1.21%+5.10%-10.86%-48.79% 140B
Average -0.45%+2.94%-8.32%+24.51% 304.24B
Weighted average by Cap. -0.19%+3.35%-7.77%+52.08%
See all sector performances

Financials

2025 *2026 *
Net sales 59.57B 51.53B 48.35B 43.82B 80.9B 5,129B 91.5B 565B 220B 2,348B 224B 219B 8,577B 71.42B 61.78B 57.97B 52.54B 96.99B 6,149B 110B 678B 264B 2,815B 268B 262B 10,283B
Net income 19.1B 16.53B 15.51B 14.05B 25.95B 1,645B 29.35B 181B 70.53B 753B 71.71B 70.16B 2,751B 25.19B 21.79B 20.45B 18.53B 34.21B 2,169B 38.7B 239B 93B 993B 94.56B 92.52B 3,627B
Net Debt 24.79B 21.44B 20.12B 18.23B 33.66B 2,134B 38.07B 235B 91.5B 977B 93.03B 91.03B 3,569B 12.19B 10.54B 9.89B 8.96B 16.55B 1,049B 18.72B 116B 44.99B 480B 45.74B 44.75B 1,755B
More financial data * Estimated data
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
Employees
47,000
More about the company
Date Price Change Volume
25-06-13 819.36 $ +0.90% 2,754,603
25-06-12 812.03 $ +0.42% 2,271,087
25-06-11 808.61 $ +0.18% 3,125,380
25-06-10 807.19 $ +4.33% 4,744,424
25-06-09 773.71 $ +0.50% 2,262,158

Delayed Quote Nyse, June 13, 2025 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
819.36USD
Average target price
951.98USD
Spread / Average Target
+16.19%
Consensus

Quarterly revenue - Rate of surprise